Literature DB >> 12239288

Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope.

Teshome Mebatsion1, Marck J M Koolen, Leonie T C de Vaan, Niels de Haas, Marian Braber, Angela Römer-Oberdörfer, Paul van den Elzen, Pieter van der Marel.   

Abstract

The nucleoprotein (NP) of Newcastle disease virus (NDV) functions primarily to encapsidate the virus genome for the purpose of RNA transcription, replication, and packaging. This conserved multifunctional protein is also efficient in inducing NDV-specific antibody in chickens. Here, we localized a conserved B-cell immunodominant epitope (IDE) spanning residues 447 to 455 and successfully generated a recombinant NDV lacking the IDE by reverse genetics. Despite deletion of NP residues 443 to 460 encompassing the NP-IDE, the mutant NDV propagated in embryonated specific-pathogen-free chicken eggs to a level comparable to that of the parent virus. In addition, a B-cell epitope of the S2 glycoprotein of murine hepatitis virus (MHV) was inserted in-frame to replace the NP-IDE. Recombinant viruses properly expressing the introduced MHV epitope were successfully generated, demonstrating that the NP-IDE not only is dispensable for virus replication but also can be replaced by foreign sequences. Chickens immunized with the hybrid recombinants produced specific antibodies against the S2 glycoprotein of MHV and completely lacked antibodies directed against the NP-IDE. These marked-NDV recombinants, in conjunction with a diagnostic test, enable serological differentiation of vaccinated animals from infected animals and may be useful tools in ND eradication programs. The identification of a mutation-permissive region on the NP gene allows a rational approach to the insertion of protective epitopes and may be relevant for the design of NDV-based cross-protective marker vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239288      PMCID: PMC136582          DOI: 10.1128/jvi.76.20.10138-10146.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope.

Authors:  M Koo; M Bendahmane; G A Lettieri; A D Paoletti; T E Lane; J H Fitchen; M J Buchmeier; R N Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Protective immunity against Newcastle disease: the role of cell-mediated immunity.

Authors:  D L Reynolds; A D Maraqa
Journal:  Avian Dis       Date:  2000 Jan-Mar       Impact factor: 1.577

3.  Nucleotide sequence and vaccinia expression of the nucleoprotein of a highly virulent, neurotropic strain of Newcastle disease virus.

Authors:  M D Ward; F J Fuller; Y Mehrotra; E V De Buysscher
Journal:  Avian Dis       Date:  2000 Jan-Mar       Impact factor: 1.577

4.  Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses.

Authors:  W Luytjes; D Geerts; W Posthumus; R Meloen; W Spaan
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.

Authors:  B P Peeters; O S de Leeuw; I Verstegen; G Koch; A L Gielkens
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

6.  Generation of recombinant lentogenic Newcastle disease virus from cDNA.

Authors:  Angela Römer-Oberdörfer; Egbert Mundt; Teshome Mebatsion; Ursula J Buchholz; Thomas C Mettenleiter
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

7.  A recombinant newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos.

Authors:  T Mebatsion; S Verstegen; L T De Vaan; A Römer-Oberdörfer; C C Schrier
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.

Authors:  H G P van Gennip; A Bouma; P A van Rijn; M N Widjojoatmodjo; R J M Moormann
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

9.  Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site.

Authors:  W Luytjes; L S Sturman; P J Bredenbeek; J Charite; B A van der Zeijst; M C Horzinek; W J Spaan
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

10.  Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): correlation with biological activities.

Authors:  P J Talbot; A A Salmi; R L Knobler; M J Buchmeier
Journal:  Virology       Date:  1984-01-30       Impact factor: 3.616

View more
  20 in total

1.  Characterization of a recombinant Newcastle disease virus vaccine strain.

Authors:  Sun-Hee Cho; Hyuk-Joon Kwon; Tae-Eun Kim; Jae-Hong Kim; Han-Sang Yoo; Man-Hoon Park; Young-Ho Park; Sun-Joong Kim
Journal:  Clin Vaccine Immunol       Date:  2008-09-03

2.  Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization.

Authors:  Raquel Martín-Folgar; Gema Lorenzo; Hani Boshra; Javier Iglesias; Francisco Mateos; Belén Borrego; Alejandro Brun
Journal:  MAbs       Date:  2010-05-02       Impact factor: 5.857

3.  Recombinant infectious bursal disease virus carrying hepatitis C virus epitopes.

Authors:  Chitra Upadhyay; Arun Ammayappan; Deendayal Patel; Imre Kovesdi; Vikram N Vakharia
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

4.  Molecular characterization of partial fusion gene and C-terminus extension length of haemagglutinin-neuraminidase gene of recently isolated Newcastle disease virus isolates in Malaysia.

Authors:  Ayalew Berhanu; Aini Ideris; Abdul R Omar; Mohd Hair Bejo
Journal:  Virol J       Date:  2010-08-08       Impact factor: 4.099

5.  Rabies virus nucleoprotein as a carrier for foreign antigens.

Authors:  Martin L Koser; James P McGettigan; Gene S Tan; Mary Ellen Smith; Hilary Koprowski; Bernhard Dietzschold; Matthias J Schnell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

6.  Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.

Authors:  Javier Castillo-Olivares; Roeland Wieringa; Tamás Bakonyi; Antoine A F de Vries; Nick J Davis-Poynter; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  An overview on the development of newcastle disease virus as an anti-cancer therapy.

Authors:  Abdul Rahman Omar; Aini Ideris; Abdul Manaf Ali; Fauziah Othman; Khatijah Yusoff; Jafri Malin Abdullah; Haryati Shila Mohamad Wali; Madihah Zawawi; Narayani Meyyappan
Journal:  Malays J Med Sci       Date:  2003-01

Review 8.  Paramyxovirus fusion and entry: multiple paths to a common end.

Authors:  Andres Chang; Rebecca E Dutch
Journal:  Viruses       Date:  2012-04-19       Impact factor: 5.048

9.  Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect.

Authors:  Ziye Pan; Jinjiao He; Lubna M Rasoul; Yunye Liu; Ruixiang Che; Yun Ding; Xiaocheng Guo; Jiarui Yang; Dehua Zou; Hua Zhang; Deshan Li; Hongwei Cao
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

10.  Rescue of a chimeric rinderpest virus with the nucleocapsid protein derived from peste-des-petits-ruminants virus: use as a marker vaccine.

Authors:  Satya Parida; Madhuchhanda Mahapatra; Sai Kumar; Subash C Das; Michael D Baron; John Anderson; Thomas Barrett
Journal:  J Gen Virol       Date:  2007-07       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.